Pepcid and Deafness neurosensory - a phase IV clinical study of FDA data

Summary:

Deafness neurosensory is reported as a side effect among people who take Pepcid (famotidine), especially for people who are male, 60+ old, also take Lortab, and have Arthritis.

The phase IV clinical study analyzes which people have Deafness neurosensory when taking Pepcid. It is created by eHealthMe based on reports of 54,527 people who have side effects when taking Pepcid from the FDA, and is updated regularly.

What is Pepcid?

Pepcid has active ingredients of famotidine. It is often used in gastroesophageal reflux disease. eHealthMe is studying from 55,775 Pepcid users. Check the latest studies of Pepcid.

What is Deafness neurosensory?

Deafness neurosensory is found to be associated with 520 drugs and 949 conditions by eHealthMe. Check the latest studies of Deafness neurosensory.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 31, 2026

54,527 people reported to have side effects when taking Pepcid.
Among them, 30 people (0.06%) have Deafness neurosensory.

Could Pepcid cause Deafness neurosensory?

Among these 30 people:

What is the gender of people who have Deafness neurosensory when taking Pepcid? *

female: 38.46 %
male: 61.54 %

What is the age of people who have Deafness neurosensory when taking Pepcid? *

What are other drugs people take besides Pepcid? *

What are other side effects people have besides Deafness neurosensory? *

Dyspnea (difficult or laboured breathing): 24 people, 80.00%
Insomnia (sleeplessness): 23 people, 76.67%
Dizziness: 20 people, 66.67%
Nausea (feeling of having an urge to vomit): 19 people, 63.33%
Pain In Extremity: 19 people, 63.33%
High Blood Pressure: 19 people, 63.33%
Headache (pain in head): 19 people, 63.33%
Pain: 19 people, 63.33%
Back Pain: 19 people, 63.33%
Anaemia (lack of blood): 19 people, 63.33%

What are the existing conditions these people have? *

Sleep Disorder: 17 people, 56.67%
Nausea (feeling of having an urge to vomit): 17 people, 56.67%
Muscle Spasms (muscle contraction): 17 people, 56.67%
Hypercalcaemia (elevated calcium (ca+) level in the blood): 17 people, 56.67%
Depression: 17 people, 56.67%
Arthritis (form of joint disorder that involves inflammation of one or more joints): 17 people, 56.67%
Sinus Disorder (disease of sinus): 2 people, 6.67%
Metastases To Bone (cancer spreads to bone): 1 person, 3.33%
High Blood Pressure: 1 person, 3.33%
Erection Problems: 1 person, 3.33%

* Approximation only. Some reports may have incomplete information.

Do you take Pepcid and have Deafness neurosensory?

- Check whether Deafness neurosensory is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Pepcid:

Pepcid (55,775 reports)

Browse all side effects of Pepcid:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Deafness neurosensory:

Deafness neurosensory (520 drugs)

Browse all the conditions that are associated with Deafness neurosensory:

Deafness neurosensory (949 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on famotidine (the active ingredients of Pepcid) and Pepcid (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.